Figure 2.
Figure 2. bFGF treatment specifically redistributes JAM-1. (A) Immunofluorescence images of JAM-1 localization in HUVECs labeled with anti–JAM-1 and phalloidin for F-actin in the absence or presence of bFGF. On bFGF treatment, JAM-1 redistributes along the cell membrane. (B) HUVECs labeled with anti–VE-cadherin and polyclonal anti–JAM-1 in the absence or presence of bFGF. Although JAM-1 redistributes, VE-cadherin remains localized at the cell-cell junction. Scale bars represent 10 μm.

bFGF treatment specifically redistributes JAM-1. (A) Immunofluorescence images of JAM-1 localization in HUVECs labeled with anti–JAM-1 and phalloidin for F-actin in the absence or presence of bFGF. On bFGF treatment, JAM-1 redistributes along the cell membrane. (B) HUVECs labeled with anti–VE-cadherin and polyclonal anti–JAM-1 in the absence or presence of bFGF. Although JAM-1 redistributes, VE-cadherin remains localized at the cell-cell junction. Scale bars represent 10 μm.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal